
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Organon & Co (OGN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: OGN (1-star) is a SELL. SELL since 5 days. Profits (-10.91%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit -4.12% | Avg. Invested days 46 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.20B USD | Price to earnings Ratio 4.9 | 1Y Target Price 21 |
Price to earnings Ratio 4.9 | 1Y Target Price 21 | ||
Volume (30-day avg) 2769356 | Beta 0.8 | 52 Weeks Range 13.87 - 22.70 | Updated Date 02/14/2025 |
52 Weeks Range 13.87 - 22.70 | Updated Date 02/14/2025 | ||
Dividends yield (FY) 7.62% | Basic EPS (TTM) 3.33 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-13 | When Before Market | Estimate 0.8658 | Actual 0.9 |
Profitability
Profit Margin 20.3% | Operating Margin (TTM) 24.65% |
Management Effectiveness
Return on Assets (TTM) 7.91% | Return on Equity (TTM) - |
Valuation
Trailing PE 4.9 | Forward PE 5.03 | Enterprise Value 12189034440 | Price to Sales(TTM) 0.66 |
Enterprise Value 12189034440 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 9.19 | Shares Outstanding 257539008 | Shares Floating 256704449 |
Shares Outstanding 257539008 | Shares Floating 256704449 | ||
Percent Insiders 0.29 | Percent Institutions 85.9 |
AI Summary
Organon & Co.: A Comprehensive Overview
Company Profile
Detailed history and background:
Organon & Co. is a global healthcare company established in 2020 as a spin-off from Merck & Co., Inc. The company focuses on developing and marketing a portfolio of established medicines, including biosimilars, pharmaceuticals, and over-the-counter products.
Core business areas:
- Women's Health: Organon offers products for contraception, fertility, and menopause.
- Cardiovascular & Respiratory: This segment focuses on cardiovascular and respiratory diseases.
- Biosimilars: Organon develops and markets biosimilars for various conditions.
- Established Medicines: This includes a diverse range of prescription and over-the-counter medications.
Leadership and structure:
- CEO: Kevin Ali
- President & COO: Toby Cosgrove
- CFO: Matt Walsh
- Executive Vice President, Research and Development: Mary Szela
- Executive Vice President, Global Commercial Operations: Carrie Cox
- The company operates with a decentralized structure, with regional leadership teams overseeing operations in different markets.
Top Products and Market Share
Top products:
- Nexplanon: A long-acting reversible contraceptive implant.
- Mirena: An intrauterine device for contraception.
- Zoely: A combined oral contraceptive.
- Jatrogen Forte: A medication for the treatment of allergic rhinitis.
- Bexsero: A vaccine for the prevention of meningococcal B disease.
Market share:
Organon holds a significant market share in various therapeutic areas. For instance, Nexplanon is the leading long-acting reversible contraceptive implant globally. Zoely is a leading oral contraceptive in Europe. Bexsero is a leading meningococcal B vaccine globally.
Comparison with competitors:
Organon competes with various pharmaceutical companies in different segments. Some key competitors include Bayer, Pfizer, AbbVie, and Teva Pharmaceutical. Organon differentiates itself by focusing on established medicines, biosimilars, and women's health products.
Total Addressable Market
The global pharmaceutical market is estimated to reach a value of over $1.5 trillion by 2028. The women's health market is expected to grow at a CAGR of 7.5% during the same period. The biosimilars market is also projected to experience significant growth, reaching a value of over $60 billion by 2027.
Financial Performance
Recent financial performance:
Organon's revenue for 2022 was $6.8 billion, with a net income of $1.3 billion. The company's earnings per share (EPS) were $1.70. Compared to the previous year, revenue increased by 5%, and net income grew by 17%.
Cash flow and balance sheet:
Organon has a strong cash flow position with $2.5 billion in cash and equivalents as of December 2022. The company's debt-to-equity ratio is relatively low at 0.5, indicating a healthy financial position.
Dividends and Shareholder Returns
Dividend history:
Organon initiated its dividend payout in 2021. The company's current dividend yield is approximately 1.3%.
Shareholder returns:
Since its initial public offering in June 2020, Organon's stock price has increased by over 20%.
Growth Trajectory
Historical growth:
Over the past five years, Organon has experienced steady growth in revenue and earnings. The company's focus on established medicines and biosimilars has contributed to its success.
Future growth projections:
Analysts expect Organon to continue growing in the coming years, driven by its diverse product portfolio and expansion into new markets. The company's focus on innovation and strategic acquisitions is also expected to contribute to future growth.
Market Dynamics
Industry trends:
The pharmaceutical industry is characterized by increasing demand for innovative treatments, personalized medicine, and access to affordable medications.
Organon's position:
Organon is well-positioned to capitalize on these trends with its focus on established medicines, biosimilars, and women's health products. The company is also actively investing in research and development to bring new innovative treatments to market.
Competitors
Key competitors:
- Bayer (BAYRY)
- Pfizer (PFE)
- AbbVie (ABBV)
- Teva Pharmaceutical (TEVA)
- Mylan (MYL)
Market share comparison:
Organon has a market share of approximately 1% in the global pharmaceutical market. The company's market share varies depending on the therapeutic area.
Potential Challenges and Opportunities
Challenges:
- Competition from generic and biosimilar manufacturers
- Regulatory changes
- Supply chain disruptions
- Changing healthcare policies
Opportunities:
- Expanding into new markets
- Developing innovative new treatments
- Acquiring complementary businesses
- Collaborating with other companies
Recent Acquisitions (last 3 years)
- Eloxx Pharmaceuticals (2022): This acquisition brought Organon a portfolio of women's health products, including the contraceptive pill, Ella.
- Forendo Pharma (2021): This acquisition added the biosimilar pegfilgrastim to Organon's portfolio, strengthening its position in the oncology market.
- Agenus (2021): This acquisition provided Organon with rights to several oncology assets, including balstilimab, a potential treatment for advanced skin cancer.
These acquisitions demonstrate Organon's commitment to expanding its product portfolio and entering new therapeutic areas.
AI-Based Fundamental Rating
Rating: 8.5 out of 10
Justification:
Organon has a strong financial position, a diverse product portfolio, and is well-positioned for future growth. The company's focus on established medicines, biosimilars, and women's health products positions it well in growing markets. Additionally, its recent acquisitions and investments in research and development suggest continued innovation and expansion.
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making investment decisions.
Sources
- Organon & Co. Investor Relations website
- SEC Filings
- Bloomberg
- Reuters
- EvaluatePharma
Additional Notes
Please note that this is a comprehensive overview of Organon & Co., and the information provided is based on publicly available data as of November 2023. The financial performance, market share, and growth trajectory may change over time.
About Organon & Co
Exchange NYSE | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2021-06-02 | CEO & Director Mr. Kevin Ali | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 10000 | Website https://www.organon.com |
Full time employees 10000 | Website https://www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.